398 related articles for article (PubMed ID: 25885411)
1. Systemic lupus erythematous and malignancy risk: a meta-analysis.
Cao L; Tong H; Xu G; Liu P; Meng H; Wang J; Zhao X; Tang Y; Jin J
PLoS One; 2015; 10(4):e0122964. PubMed ID: 25885411
[TBL] [Abstract][Full Text] [Related]
2. Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis.
Clarke AE; Pooley N; Marjenberg Z; Langham J; Nicholson L; Langham S; Embleton N; Wang X; Desta B; Barut V; Hammond ER
Semin Arthritis Rheum; 2021 Dec; 51(6):1230-1241. PubMed ID: 34710720
[TBL] [Abstract][Full Text] [Related]
3. Primary Sjögren's syndrome is associated with increased risk of malignancies besides lymphoma: A systematic review and meta-analysis.
Zhong H; Liu S; Wang Y; Xu D; Li M; Zhao Y; Zeng X
Autoimmun Rev; 2022 May; 21(5):103084. PubMed ID: 35341972
[TBL] [Abstract][Full Text] [Related]
4. Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis.
Ni J; Qiu LJ; Hu LF; Cen H; Zhang M; Wen PF; Wang XS; Pan HF; Ye DQ
Lupus; 2014 Mar; 23(3):284-92. PubMed ID: 24429300
[TBL] [Abstract][Full Text] [Related]
5. The risk of lymphoma development in autoimmune diseases: a meta-analysis.
Zintzaras E; Voulgarelis M; Moutsopoulos HM
Arch Intern Med; 2005 Nov; 165(20):2337-44. PubMed ID: 16287762
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies.
Shang W; Ning Y; Xu X; Li M; Guo S; Han M; Zeng R; Ge S; Xu G
PLoS One; 2015; 10(5):e0126016. PubMed ID: 25973882
[TBL] [Abstract][Full Text] [Related]
7. Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis.
Liang Y; Yang Z; Qin B; Zhong R
Ann Rheum Dis; 2014 Jun; 73(6):1151-6. PubMed ID: 23687261
[TBL] [Abstract][Full Text] [Related]
8. The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis.
Song L; Wang Y; Zhang J; Song N; Xu X; Lu Y
Arthritis Res Ther; 2018 Dec; 20(1):270. PubMed ID: 30522515
[TBL] [Abstract][Full Text] [Related]
9. Screening for second malignancies in mycosis fungoides: non-Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma.
Goyal A; O'Leary D; Goyal K; Rubin N; Janakiram M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1821-1829. PubMed ID: 34013554
[TBL] [Abstract][Full Text] [Related]
10. Family history of hematopoietic malignancy and risk of lymphoma.
Chang ET; Smedby KE; Hjalgrim H; Porwit-MacDonald A; Roos G; Glimelius B; Adami HO
J Natl Cancer Inst; 2005 Oct; 97(19):1466-74. PubMed ID: 16204696
[TBL] [Abstract][Full Text] [Related]
11. Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies.
Apor E; O'Brien J; Stephen M; Castillo JJ
Leuk Res; 2014 Sep; 38(9):1067-71. PubMed ID: 25052307
[TBL] [Abstract][Full Text] [Related]
12. Systemic lupus erythematosus and malignancies risk.
Mao S; Shen H; Zhang J
J Cancer Res Clin Oncol; 2016 Jan; 142(1):253-62. PubMed ID: 26319223
[TBL] [Abstract][Full Text] [Related]
13. Managing cancer risk in patients with systemic lupus erythematous.
Ladouceur A; Bernatsky S; Ramsey-Goldman R; Clarke AE
Expert Rev Clin Immunol; 2018 Oct; 14(10):793-802. PubMed ID: 30183456
[TBL] [Abstract][Full Text] [Related]
14. Systemic lupus erythematous increased lung cancer risk: Evidence from a meta-analysis.
Wu Y; Hou Q
J Cancer Res Ther; 2016; 12(2):721-4. PubMed ID: 27461640
[TBL] [Abstract][Full Text] [Related]
15. Hodgkin's lymphoma in systemic lupus erythematosus.
Bernatsky S; Ramsey-Goldman R; Isenberg D; Rahman A; Dooley MA; Sibley J; Boivin JF; Joseph L; Armitage J; Zoma A; Clarke A
Rheumatology (Oxford); 2007 May; 46(5):830-2. PubMed ID: 17255135
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and risk factors of infection in patients with systemic lupus erythematosus: A systematic review and meta-analysis of observational studies.
Yuan Q; Xing X; Lu Z; Li X
Semin Arthritis Rheum; 2020 Oct; 50(5):1022-1039. PubMed ID: 32911280
[TBL] [Abstract][Full Text] [Related]
17. Malignancy in systemic lupus erythematosus: what have we learned?
Bernatsky S; Ramsey-Goldman R; Clarke AE
Best Pract Res Clin Rheumatol; 2009 Aug; 23(4):539-47. PubMed ID: 19591783
[TBL] [Abstract][Full Text] [Related]
18. Bidirectional relationship between systemic lupus erythematosus and non-Hodgkin's lymphoma: a nationwide population-based study.
Wang LH; Wang WM; Lin SH; Shieh CC
Rheumatology (Oxford); 2019 Jul; 58(7):1245-1249. PubMed ID: 30726952
[TBL] [Abstract][Full Text] [Related]
19. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study.
Mudie NY; Swerdlow AJ; Higgins CD; Smith P; Qiao Z; Hancock BW; Hoskin PJ; Linch DC
J Clin Oncol; 2006 Apr; 24(10):1568-74. PubMed ID: 16520465
[TBL] [Abstract][Full Text] [Related]
20. Association Between Systemic Lupus Erythematosus and Cancer Morbidity and Mortality: Findings From Cohort Studies.
Zhang M; Wang Y; Wang Y; Bai Y; Gu D
Front Oncol; 2022; 12():860794. PubMed ID: 35600353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
